SCHEMBL3962620

SCHEMBL3962620

CCCCCCCCCCCCCCCCCC(=O)c1nc2ccccc2o1

nearest known ligand 0.85

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
FAAH O00519 17/20 0.85
CES1 P23141 4/20 0.85
DAGLA Q9Y4D2 7/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3964233 0.92 FAAH (1.00) FAAHCES1DAGLA
SCHEMBL14562869 0.88 FAAH (0.67) FAAHCES1DAGLA
SCHEMBL5672032 0.82 DAGLA (0.67) FAAHCES1DAGLA
SCHEMBL6062417 0.82 DAGLA (0.67) FAAHCES1DAGLA
SCHEMBL4051507 0.82 DAGLA (0.67) FAAHCES1DAGLA
SCHEMBL11937009 0.82 FAAH (0.59) FAAHCES1DAGLA
SCHEMBL24934422 0.81 DAGLA (0.64) FAAHCES1DAGLA
SCHEMBL6465056 0.80 DAGLA (0.64) FAAHCES1DAGLA
SCHEMBL27805184 0.80 DAGLA (0.67) FAAHCES1DAGLA
SCHEMBL3968868 0.80 FAAH (1.00) FAAHCES1DAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270421-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2009-10-29 US disclosed
US-7560570-B2 Inhibitors of fatty acid amide hydrolase THE SCRIPPS RESEARCH INSTITUTE (US) 2009-07-14 US disclosed
US-20050239785-A1 Inhibitors of fatty acid amide hydrolase THE SCRIPPS RESEARCH INSTITUTE (US) 2005-10-27 US disclosed
US-6891043-B2 Inhibitors of fatty acid amide hydrolase THE SCRIPPS RESEARCH INSTITUTE (US) 2005-05-10 US disclosed
US-20030092734-A1 Inhibitors of fatty acid amide hydrolase THE SCRIPPS RESEARCH INSTITUTE 2003-05-15 US disclosed
US-6462054-B1 ALPHA KETO HETEROCYCLIC PHARMACOPHORE; COMPLEMENTARY BINDING BY ELECTROPHILIC CARBONYL AND WEAKLY BASIC NITROGEN OF SUCH AS OXAZOLOPYRIDINE GROUP; SLEEP AIDS OR ANALGESICS; PRESERVING ENDOGENOUS LEVELS OF OLEAMIDE AND ANANDAMIDE THE SCRIPPS RESEARCH INSTITUTE 2002-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270421-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, CNR2 FAAH 1/4885CES1 23/4885DAGLA 131/4885
US-20030092734-A1 Inhibitors of fatty acid amide hydrolase FAAH, FAAH2, CNR2 FAAH 1/4885CES1 9/4885DAGLA 202/4885
US-20050239785-A1 Inhibitors of fatty acid amide hydrolase FAAH, FAAH2, CNR2 FAAH 1/4885CES1 23/4885DAGLA 131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.